Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Total Debt
Short-term and long-term borrowings combined.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Total Debt · Q2 FY2027 · quarter ended Sep 2026
Total debt rises 24.0% from a year ago
Total debt stood at ₹72.6B at the end of Q2 FY2027, up 24.0% from a year earlier and up 0.9% from the prior quarter. Over 3 fiscal years it compounded at +77.9% a year.
Context
- Total debt amounted to 12.6% of total assets at the end of Q2 FY2027, up 1.8 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +24.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
INR · from the balance sheet
- Latest · FY2026
- 75.81B INR
- Year-over-year change
- +62.1%
- 4-year CAGR
- +22.3%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 75.81B | +62.1% |
| FY2025 | 2025-03-31 | 46.77B | +133.6% |
| FY2024 | 2024-03-31 | 20.02B | +48.6% |
| FY2023 | 2023-03-31 | 13.47B | -60.2% |
| FY2022 | 2022-03-31 | 33.85B | — |
Total Debt vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +24.0% is the highest of 8, against a peer median of -4.4%.
- Total debt amounts to 12.6% of total assets for RDY, versus a peer median of 41.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹72.6B INR | +24.0% | +77.9% | 12.6% | |
| Jun 2026 | $20.78B USD | -4.4% | +0.7% | 83.8% | |
| Jun 2026 | $16.87B USD | -3.7% | -6.9% | 42.3% | |
| Jun 2026 | $13.63B USD | -7.7% | -9.0% | 38.9% | |
| Dec 2025 | £8.59B GBP | -14.9% | -6.3% | 26.4% | |
| Jun 2026 | $2.79B USD | +8.1% | -1.3% | 73.9% | |
| Mar 2026 | $686.38M USD | +5.2% | +85.6% | 41.6% | |
| Mar 2026 | $327.76M USD | -47.4% | +4.3% | 23.0% | |
| Peer median (excluding RDY) | — | -4.4% | -1.3% | 41.6% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.85B | 5.78B | 7.11B | 14.65B | 15.06B |
| Short-term Investments | 29.51B | 56.02B | 74.36B | 43.25B | 71.01B |
| Net Receivables | 80.27B | 83.2B | 95.34B | 109.79B | 99.22B |
| Inventory | 50.88B | 48.67B | 63.55B | 71.09B | 75.02B |
| Other Current Assets | 5.2B | 6.41B | 2.94B | 4.56B | 35.69B |
| Total Current Assets | 181.86B | 204.25B | 248.05B | 250.11B | 296B |
| Property, Plant & Equipment (Net) | 62.17B | 66.46B | 76.89B | 97.76B | 113.63B |
| Goodwill | 4.42B | 4.25B | 4.25B | 11.81B | 12.64B |
| Intangible Assets | 27.25B | 30.85B | 36.95B | 96.8B | 102.98B |
| Long-term Investments | 7.99B | 5.36B | 5.26B | 15.2B | 16.04B |
| Tax Assets | 8.2B | 7.2B | 10.77B | 18.51B | 21.99B |
| Other Non-current Assets | 948M | 3.49B | 5.35B | 2.79B | 4.59B |
| Total Non-current Assets | 110.97B | 117.6B | 139.47B | 242.88B | 271.88B |
| Total Assets | 292.83B | 321.85B | 387.52B | 492.99B | 567.88B |
| Account Payables | 15.97B | 17.86B | 21.55B | 20.05B | 32.75B |
| Short-term Debt | 27.08B | 11.19B | 12.72B | 38.05B | 63.85B |
| Tax Payables | 1.62B | 2.14B | 2.34B | 3.03B | 0 |
| Deferred Revenue | 2.58B | 1.98B | 1.44B | 1.98B | 0 |
| Other Current Liabilities | 6.76B | 9.19B | 11.42B | 13.52B | 63.43B |
| Total Current Liabilities | 94.02B | 85.85B | 96.04B | 130.39B | 164.25B |
| Long-term Debt | 3.8B | 0 | 3.8B | 3.8B | 11.96B |
| Deferred Tax Liabilities | 60M | 833M | 909M | 14.11B | 15.26B |
| Deferred Revenue (Non-current) | 1.6B | 1.56B | 1.19B | 1.16B | 0 |
| Other Non-current Liabilities | 882M | 1.35B | 2.84B | 2.3B | 3.48B |
| Total Non-current Liabilities | 8.29B | 5.02B | 10.93B | 25.43B | 30.7B |
| Total Liabilities | 102.3B | 90.86B | 106.97B | 155.82B | 194.95B |
| Common Stock | 832M | 833M | 834M | 834M | 818.47M |
| Retained Earnings | 175.71B | 215.59B | 265.26B | 315.79B | 345.02B |
| Accumulated OCI | 755M | 886M | 653M | 3.98B | 10.5B |
| Other Stockholders Equity | 5.07B | 4.71B | 3.86B | 3.74B | 3.9B |
| Minority Interest | 0 | 0 | 0 | 3.78B | 3.33B |
| Total Equity | 190.53B | 230.99B | 280.55B | 337.17B | 372.92B |
| Total Debt | 33.85B | 13.47B | 20.02B | 46.77B | 75.81B |
| Net Debt | 18.99B | 7.69B | 12.91B | 32.11B | 60.75B |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.